Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > ORGANIZATION
ORGANIZATION
- FPMAJ Adopts FY2021 Project Plans with Focus on Pricing Reform
March 19, 2021
- Trade Groups Push Proper Pricing of Innovative Drugs to Restore Attractiveness of Japan: LDP Confab
March 19, 2021
- With Aducanumab in Mind, Outgoing Chuikyo Payer Rep Floats Rule to Reward Cost Cuts for Pricey Meds
March 18, 2021
- Nichi-Iko Suspended from JGA Membership
March 10, 2021
- Fast-Track Approval System, New Pricing Rules Needed for Therapeutic Apps: DTx Consortium
March 5, 2021
- Ono President Apologizes to JPMA After 2 Employees Are Indicted for Bribery
February 22, 2021
- 76% Sees Healthcare as Top Priority in COVID-19 Response: PhRMA Japan Survey
February 19, 2021
- PhRMA Japan Chief Urges Govt to Return to Pro-Innovation Path, Airs Grievances over Decision-Making on Off-Year Price Cuts
February 19, 2021
- Kobayashi Kako Expelled from JGA over Drug Mix-Up
February 10, 2021
- PhRMA Prods Japan to Harness Power of RWD in Drug Development, Medical Care Evaluation
February 3, 2021
- JPMA, National Centers to Build Integrated Database for Drug Discovery; 1st Focus on Neurology/Psychiatry, Immune/Inflammation
January 26, 2021
- 3 Indicted Wholesalers Barred from JCHO/NHO Bids, but Can Sell Single-Channel Drugs to Ensure Access
January 26, 2021
- JPMA Exec Raps Off-Year Re-Pricing Plan, Says It Significantly Mars Predictability
January 22, 2021
- Generic Use Targets Should Be Set by City/Ward in Major Prefectures: Professor
January 14, 2021
- Yaz Generics to Carry Single Brand Name of DroEthi
January 13, 2021
- JPMA Chief Vows Renewed Efforts to Deliver COVID-19 Drugs, Vaccines as Japan Declares 2nd Emergency
January 12, 2021
- Japan Pharma Lobbies Shifting to Manabe/Okada Leadership? Their Abilities Will Be Tested as Industry Grapples with Thorny Issues
January 7, 2021
- 5% Discrepancy Line a Bad Surprise, FPMAJ Exec Says Drug Prices Will Now Go Down at Double Speed with Annual Re-Pricing
January 5, 2021
- First Time FPMAJ’s Supply Coordination Scheme Invoked for 13 APIs Tied to Kobayashi Kako
January 5, 2021
- Corporate Culture, Attitude of Management at Root of Kobayashi Kako Scandal: MHLW Official
January 5, 2021
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…